The Technical Analyst
Hillstream BioPharma, [HILS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Hillstream BioPharma, Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.66% $0.237
America/New_York / 22 sep 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.17 mill |
| EPS: | -0.700 |
| P/E: | -0.339 |
| Earnings Date: | Nov 13, 2023 |
| SharesOutstanding: | 17.60 mill |
| Avg Daily Volume: | 0.685 mill |
| RATING 2023-10-20 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.339 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -0.339 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.146 - 0.216 ( +/- 19.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-15 | Milby Randy | Buy | 29 000 | Common Stock |
| 2023-11-30 | Milby Randy | Buy | 10 000 | Common Stock |
| 2023-11-07 | Bui Lynne A. | Buy | 25 000 | Options (right to buy) |
| 2023-11-07 | Appajosyula Sireesh | Buy | 25 000 | Options (right to buy) |
| 2023-11-07 | Anderson Kelly | Buy | 50 000 | Options (right to buy) |
| INSIDER POWER |
|---|
| 94.32 |
| Last 99 transactions |
| Buy: 3 498 545 | Sell: 667 792 |
Forecast:
01:40 - $0.176
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.237 (5.66% ) |
| Volume | 0.313 mill |
| Avg. Vol. | 0.685 mill |
| % of Avg. Vol | 45.74 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HILS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HILS
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
Latest Press Releases
2023-09-22 08:30:00 - Press Release
Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset And Announces Corporate Name Change To Tharimmune, Inc.
Expects to launch and complete a phase 1 trial in q4 2023 tharimmune to begin trading under new ticker, thar, on monday september 25, 2023 bridgewater, nj / accesswire / september 22, 2023 / hillstream biopharma inc., (nasdaq:hils), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases announced a corporate name change to tharimmune, inc., ("tharimmune"). the corporate name change is based on the greek word "thÁrros", translated to mean courage and reflects the transformation of the company into a patient-focused, clinical development organization.
2023-09-11 11:51:00 - Press Release
Hillstream Enters Into An Exclusive Option Agreement To Acquire A Clinical Stage Asset For Chronic Pruritis
Anticipate completion of phase 1 & phase 2 clinical trials in chronic pruritis over the next approximately 12 months
2023-09-08 14:30:00 - Press Release
Hillstream Biopharma To Present At H.c. Wainwright 25th Annual Global Investment Conference September 11-13
Bridgewater, n.j., sept. 08, 2023 (globe newswire) -- hillstream biopharma, inc. (nasdaq: hils) ("hillstream" or the "company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the h.c. wainwright 25th annual global investment conference, being held in person and virtually from september 11-13, 2023.
2023-08-09 08:47:00 - Press Release
Hillstream Biopharma To Present At The Sidoti Micro-cap Virtual Conference On August 16-17, 2023
Bridgewater, n.j., aug. 09, 2023 (globe newswire) -- hillstream biopharma, inc. (nasdaq: hils) ("hillstream" or the "company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced that it will be attending the annual sidoti micro-cap virtual conference being held on august 16-17, 2023.
2023-07-20 08:00:00 - Press Release
Hillstream Advances Next-gen Multispecific Antibodies For Solid Tumors With Lead Her2/her3 Program, Hsb-3215
Collaboration adds multiple modular swappable antigen recognition regions to lead program, hsb-3215, a bispecific antibody targeting novel epitopes on her2/her3 receptors
Latest News
2023-09-08 14:30:00 - GlobeNewsWire
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held in person and virtually from September 11-13, 2023.
2023-08-09 08:47:00 - GlobeNewsWire
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced that it will be attending the Annual Sidoti Micro-Cap Virtual Conference being held on August 16-17, 2023.
2023-05-02 08:47:00 - GlobeNewsWire
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in Washington, D.C. BRIDGEWATER, N.J.
2023-04-28 08:54:19 - InvestorPlace
Why Is Hillstream BioPharma (HILS) Stock Down 57% Today?
Hillstream BioPharma (NASDAQ: HILS ) stock is taking a beating on Friday after the company revealed plans for a public offering of its shares. Hillstream BioPharma is selling 5.3 million shares of HILS stock in this public offering.
2023-04-03 22:49:50 - 24/7 Wall Street
10 Best-Performing Penny Stocks in the Health Care Sector
2023-02-13 16:15:00 - GlobeNewsWire
Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET
Company's Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach $11 Billion in 2028
2023-02-11 11:00:00 - PennyStocks
The Benefits of Investing in Penny Stocks in the Long Term
Why investing in penny stocks in the long term could be the right choice The post The Benefits of Investing in Penny Stocks in the Long Term appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-01-31 11:32:45 - InvestorPlace
Why Is Hillstream BioPharma (HILS) Stock Up 100% Today?
It's not every day that you hear about Hillstream BioPharma (NASDAQ: HILS ) in the financial headlines. Today, however, HILS stock is skyrocketing more than 100% on heavy trading volume.
2023-01-31 09:30:53 - PennyStocks
7 Top Penny Stocks To Watch With Big News This Week
2023-01-17 11:29:00 - GlobeNewsWire
Hillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023
BRIDGEWATER, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the Virtual Sidoti Micro-Cap Conference being held on January 18-19, 2023.